The Lundquist Institute investigator is the lead author of a JAMA Open Network publication that positively evaluates the EyeArt AI system for preventing diabetic vision loss


Study Examines the Performance of the EyeArt AI System for Detecting Eyes with More Than Mild Diabetic Retinopathy (mtmDR) and Vision Threatening Diabetic Retinopathy (vtDR)

LOS ANGELES, November 16, 2021 / PRNewswire / – The Lundquist Institute Investigator Eli Ipp, MD, and a multi-center team of researchers evaluated the performance of the EyeArt AI system in a study published in JAMA Open Network. Dr Ipp and his co-researchers found that the accuracy of EyeArt The AI ​​system was high in detecting mtmDR (sensitivity 96% and specificity 88%) and vtDR (sensitivity 97% and specificity 90%). The study demonstrates the ability of EyeArt system for accurately detecting mtmDR and vtDR without medical supervision or the need for dilation in most individuals, thereby facilitating eye examinations of diabetics in non-specialized facilities and allowing for accelerated referral of vision-threatening diabetic retinopathy. It is the first AI-based system that identifies vtDR, the most severe form of RD that puts patients at the highest risk of blindness. The good results of the EyeArt prospective pivotal multicenter clinical trial (NCT03112005) were published as an original survey in JAMA Network Open, a peer-reviewed medical journal published by the American Medical Association. The article is titled “Pivotal evaluation of an artificial intelligence system for the autonomous detection of referred and vision-threatening diabetic retinopathy.

“More than 400 million people worldwide have diabetes and about a third of them can develop diabetic retinopathy, which is the leading cause of vision loss in working-age adults in most countries,” said Eli Ipp, MD, researcher at Lundquist Institute, professor of medicine, David Geffen School from medicine to UCLA, chief of the diabetes and metabolism section at Harbor-UCLA Medical Center, and the first author of the EyeArt publication on JAMA Network Open. “By simplifying and improving the efficiency of retinal screening for diabetes, the EyeArt technology has the potential to help save the vision of millions of people around the world. The EyeArt the pivotal trial was well designed and executed, and we are delighted that it is now published by JAMA Network Open. “

The EyeArt® AI System was developed by Eyenuk, Inc. with funding from the US National Institutes of Health (NIH) and is validated by the UK National Health Service (NHS).

Contact for the Lundquist Institute:
Max Benavidez [email protected] 310-200-2682


Show original content: to-prevent-diabetic-vision-loss-301426027.html

SOURCE The Lundquist Institute


Comments are closed.